Effect_of_daily_etidronate_on_the_osteolysis_of_multiple_myeloma._Progressive_bone_disease_in_multiple_myeloma_frequently_leads_to_osteolysis,_bone_resorption,_pathologic_fractures,_vertebral_compression,_and_hypercalcemia._We_conducted_a_double-blind_study_in_173_newly_diagnosed_multiple_myeloma_patients_of_etidronate_disodium_(EHDP),_a_diphosphonate_compound_that_reduces_bone_resorption_by_inhibiting_osteoclastic_activity._The_patients_were_randomly_assigned_to_receive_oral_EHDP_5_mg/kg/d_or_placebo_until_death_or_discontinuation_due_to_intolerance_or_refusal._The_extent_of_vertebral_deformity_was_measured_by_a_vertebral_index_as_well_as_height._The_frequency_of_pathologic_fractures,_hypercalcemia,_and_bone_pain_was_regularly_assessed,_as_well_as_size_and_number_of_osteolytic_lesions._All_patients_received_melphalan_and_prednisone_daily_for_4_days_every_4_weeks_as_the_primary_chemotherapy_for_their_disease._Although_the_repeated_measures_analysis_showed_a_significant_height_loss,_there_was_no_difference_between_treatment_arms_(P_=_.98)._There_was_no_significant_difference_in_bone_pain,_episodes_of_hypercalcemia,_or_development_of_pathologic_fractures._Patients_on_EHDP_showed_less_deterioration_in_their_vertebral_index,_but_this_difference_only_approached_statistical_significance_(P_=_.07)._We_conclude_that_EHDP_therapy_used_in_this_dosage_schedule_does_not_have_a_clinically_significant_impact_in_multiple_myeloma.